A phase II clinical trial of consolidation treatment with iodine I 131 tositumomab for multiple myeloma

Trial Profile

A phase II clinical trial of consolidation treatment with iodine I 131 tositumomab for multiple myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Iodine-131 tositumomab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 14 Aug 2012 Planned end date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 14 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top